GenomeQuest Appoints Dr. Mark Boguski to Panel of Science Advisors
GenomeQuest, Inc., a world leader in Sequence Data Management (SDM), announceS the appointment of Mark Boguski, MD, PhD, to its panel of science advisors.
Westborough, MA (Vocus) August 28, 2009
GenomeQuest, Inc., a world leader in Sequence Data Management (SDM) (http://www. genomequest. com), today announced the appointment of Mark Boguski, MD, PhD, to its panel of science advisors.
A twenty-year veteran of genome research, Dr. Boguski is an elected member of the Institute of Medicine of the National Academy of Sciences and is currently on the faculty of Harvard Medical School at the Center for Biomedical Informatics and the Department of Pathology at Beth Israel Deaconess Medical Center. Previously, he served as vice president of the Novartis Institutes for Biomedical Research, as senior vice president at Rosetta Inpharmatics (acquired by Merck) and was a founding member of the National Center for Biotechnology Information.
GenomeQuest CEO, Ron Ranauro comments, “We’re thrilled to have Mark on our science panel. He is in a unique position – he is world renown in his knowledge of and practice in the science of genomics, the technology of next generation sequencing (NGS), and the software of bioinformatics. No doubt, he will help GenomeQuest to converge these three powerful forces and create SDM solutions and applications that help take life sciences forward.”
Dr. Boguski adds, “I’m very pleased to join the GenomeQuest team – SDM is certainly critical to and an enabler of the transformation of life sciences. If NGS technology is like the original IBM PC, GQ has the potential to become the standard operating system all the way through to precision diagnostics in a patient care environment.”
Immediately, Dr. Boguski will become a contributing member of the NGS Executive Briefings. GenomeQuest recently completed a related global survey through Cambridge Healthtech Institute. One of the primary findings was that, while most research organizations are aggressively moving to NGS, most executives would like to understand and explore the opportunity more fully. Therefore, GenomeQuest, with its science advisor and industry partners, is holding a series of executive-level briefings on strategic issues around NGS.
The news follows last month’s announcement of GenomeQuest 6.0Beta (http://web2.genomequest. com/product/our-product. html), which introduced a new category of functionality, accessibility, and methods to genomics researchers and organizations seeking to fundamentally improve the performance of their discovery process and broadly prepare for NGS.
To contact Dr. Boguski, please email mark_boguski@hms. harvard. edu or call 617.432.7375. Learn more about Genomequest6.0Beta at www. genomequest. com.
About GenomeQuest
GenomeQuest, the leader in sequence data management (SDM) helps genomic researchers and their organizations make great discoveries far faster. Over 160 leading life science companies use GenomeQuest for mission-critical work, including 18 of the top 20 pharmaceuticals.
Using GenomeQuest, organizations improve the performance of their discovery process and broadly prepare for next generation sequencing (NGS). Researchers perform discoveries, manage and share sequence data, and access the world's largest collection of reference databases from a web-browser and personalized dashboard. Bioinformatics managers customize discovery workflows and unify their sequence data environment using the open platform. IT and business managers efficiently scale to broad utilization of next generation sequencing in their discovery operations using the GQ-Engine.
Learn more at www. genomequest. com
###
